GSK plc (LON:GSK) Stock Now Rated "Hold" by Sell-Side Analysts

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate GSK “Hold” overall: Of eight firms covering the stock, four rate it hold, three buy and one sell; the average 12-month price target is GBX 2,145.
  • GSK shares opened at GBX 1,851.50, within a 52-week range of GBX 1,690–2,282. Recent broker targets ranged from GBX 1,975 at RBC to GBX 2,500 at Jefferies.
  • For its latest reported quarter, GSK posted earnings of GBX 54.60 per share and revenue of GBX 888.70 billion. Insiders also purchased a combined 2,151 shares over the past three months.
  • MarketBeat previews the top five stocks to own by December 1st.

GSK plc (LON:GSK - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is GBX 2,145.

A number of brokerages recently weighed in on GSK. Royal Bank Of Canada started coverage on shares of GSK in a report on Tuesday, September 8th. They set a "sector perform" rating and a GBX 1,975 price objective for the company. Berenberg Bank reaffirmed a "buy" rating and issued a GBX 2,200 price objective on shares of GSK in a research report on Tuesday, November 3rd. Jefferies Financial Group restated a "buy" rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, October 20th. Finally, Deutsche Bank restated a "hold" rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, November 10th.

Get Our Latest Stock Analysis on GSK

GSK Price Performance

LON GSK opened at GBX 1,851.50 on Thursday. The company has a market capitalization of £74.23 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28. GSK has a fifty-two week low of GBX 1,690 and a fifty-two week high of GBX 2,282. The business's fifty day moving average is GBX 1,850.76 and its 200 day moving average is GBX 1,952.50. The company has a debt-to-equity ratio of 126.38, a quick ratio of 0.73 and a current ratio of 0.86.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. The business had revenue of GBX 888.70 billion during the quarter. Sell-side analysts predict that GSK will post 175.98 earnings per share for the current year.

Insider Activity at GSK

In other news, insider Anne Beal purchased 637 shares of GSK stock in a transaction dated Friday, September 18th. The shares were purchased at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business's stock in a transaction that occurred on Friday, September 18th. The stock was purchased at an average price of GBX 1,881 per share, for a total transaction of £28,215. In the last three months, insiders bought 2,151 shares of company stock valued at $6,021,921. Corporate insiders own 0.20% of the company's stock.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Recommended Stories

Analyst Recommendations for GSK (LON:GSK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines